Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer
Lijun Jin, Lu Han, Jing Zeng · 2026
Read Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer by Lijun Jin, Lu Han, Jing Zeng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13190414.txt.
Description
Jin, Han, and Zeng weigh the cost worth of a new lung drug next to plain chemo. The drug, sac-TMT, serves as a next step for EGFR-changed lung cancer. Cases in view had grown worse past the first drug round. The view is that of the health system in China. Two math frames do the weigh: a split-life frame and a Markov frame. Trial facts come from the OptiTROP-Lung04 study.
In the split-life frame, sac-TMT cost near 64,949 more in dollars. It gave 0.74 more years of sound life in that frame. The cost per sound year came to near 87,922 dollars. The Markov frame gave a like tale at near 78,132 dollars. Both sums sit far past the pay bar used, three times yearly output per head.
Catalog record
| CREATOR | Lijun Jin, Lu Han, Jing Zeng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |